neurodegenerative diseases
Conditions
Interventions
Treatment group:Therapeutic dosage: 6 treatments per day, with each treatment combination consisting of 1800 pulses + 50-minute intervals +1800 pulses
Treatment frequency: Five times a week for a total of four weeks.
The sequence of stimulation on both sides is random, with an interval of 1 minute.
The therapeutic effect is evaluated once every two
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18-65 years old; 2. Clinical symptoms, signs and electrophysiological examinations suggest that the patient has neurodegenerative diseases, including but not limited to Parkinson's disease (PD), motor neuron disease (MND), progressive supranuclear palsy (PSP), multiple system atrophy (SMA), and corticobasal ganglia degeneration (CBD). The diagnosis of PD is divided into clinically confirmed PD and clinically likely PD. The inclusion criteria are detailed in the "Diagnostic Criteria for Parkinson's Disease in China (2016 Edition)". The inclusion criteria for MND can be found in the "Chinese Expert Consensus on the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis 2022". For details of MSA, please refer to the "Chinese Expert Consensus on Diagnostic Criteria for Multiple System Atrophy". PSP: The diagnosis is divided into confirmed PSP, likely PSP, possible PSP and suggested PSP. For the inclusion and exclusion criteria, please refer to the updated PSP diagnostic criteria published by the PSP Collaboration of the International Society for Movement Disorders (MDS) in 2017 and "New Insights into the Diagnosis of Progressive Supronuclear Palsy". 3. There are motor dysfunction in the upper or lower limbs, including but not limited to increased muscle tone, balance disorders, abnormal posture and gait, etc. 4. With or without a family history; 5. The dosage of the drug treatment remained stable for two months.
Exclusion criteria
Exclusion criteria: 1. History of drug abuse or other abuses within the past six months; 2. Adjustment of drug treatment during rTMS treatment; 3. Previous history of epilepsy or history of first-degree relatives; 4. Patients who have been found to have severe systemic diseases such as heart, lung, liver and kidney through laboratory tests and examinations and whose conditions cannot be controlled by conventional medication; 5. Patients with severe depression or anxiety (HAMD-17 score of 18 or above; HAMA score of 21 or above), or those diagnosed with other mental disorders; 6. Patients whose life expectancy is less than one year due to reasons other than neurodegenerative diseases 7. Women of childbearing age who are pregnant or planning to become pregnant; 8. Individuals with pacemakers, cochlear implants or other metal foreign bodies, or any electronic devices implanted in their bodies, or those with contraindications for MRI scans such as claustrophobia, or contraindications for TMS treatment; 9. Those who had received other neuroregulation treatments such as TMS, transcranial electrical stimulation, and transcranial focused ultrasound in the 3 months prior to enrollment; 10. Patients with other abnormal examination results who are determined by the researchers to be unsuitable for participating in this trial, etc. 11. Unable to cooperate in completing the follow-up due to geographical or other reasons; 12. Those who are participating in other clinical research trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Berg Balance Scale Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| ALSFRS-R scale score;Modified Ashworth Scale (MAS) score;Timed Instant Walking (TUG) test;10-meter walking test time (10MWT); | — |
Countries
China
Contacts
Public ContactDongsheng Fan
Peking University Third Hospital
Outcome results
None listed